Chitosan–HPMC-blended microspheres as a vaccine carrier for the delivery of tetanus toxoid
Source abstract
Abstract
The purpose of this research was to develop a suitable and alternate adjuvant for the tetanus toxoid (TT) vaccine that induces long term immunity after a single-dose immunization. In our study, the preformulation studies were carried out by using different ratios (7/3, 8/2, and 9/1) of chitosan-hydroxypropyl methylcellulose (HPMC)-blended empty microspheres. Moreover, TT was stabilized with heparin (at heparin concentrations of 1%, 2%, 3%, and 4% w/v) and encapsulated in ideal chitosan - HPMC (CHBMS) microspheres, by the water-in-oil-in-water (W/O/W) multiple emulsion method. The vaccine entrapment and the in vitro release efficiency of the CHBMS was evaluated for a period of 90 days. The release of antigens from the microspheres was determined by ELISA. Antigen integrity was investigated by SDS-PAGE. From the optimization studies, it was found that a chitosan/HPMC ratio of 8/2 produced a good yield, with microspheres that were spherical, regular and uniformly-sized. In the CHBMS, a heparin concentration of 3% w/v resulted in well-sustained antigen delivery for a period of 90 days. It was found that the characteristics of initial release could be observed in 2 days, followed by a constant release, and an almost 100% complete release in 90 days. From the in vitro release characteristics, the ideal batch of CHBMS (3% w/v heparin) was evaluated for in vivo studies by the antibody induction method. The antibody levels were measured for different combinations for the period of 9 months, and finally, with a second booster dose after 1 year. In conclusion, it was observed that CHBMS (combination-1) resulted in the antibody level of 4.5 IU/mL of guinea pig serum, and the level was 3.5 IU/mL for the Central Research Institute's alum-adsorbed tetanus toxoid (CRITT) (combination 2), after 1 year, with a second booster dose. This novel approach of using CHBMS may have potential advantages for single-step immunization with vaccines.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · RNA Interference and Gene Delivery · Advancements in Transdermal Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemical Engineering, Hanseo University, Seosan, Chungcheongnam-do, South Korea
References (35)
Show source-provided references
1. Alpar HO · Proc Int Cont Rel Bioact Mater · 1994 · 21 · 867
2. 10.1016/j.gmbhs.2011.10.00110.1016/j.gmbhs.2011.10.001 ↗
3. 10.1016/j.jiec.2013.09.02610.1016/j.jiec.2013.09.026 ↗
4. 10.1016/S0168-3659(00)00308-410.1016/S0168-3659(00)00308-4 ↗
5. 10.1016/j.ejpb.2004.10.00610.1016/j.ejpb.2004.10.006 ↗
6. 10.1021/js960047b10.1021/js960047b ↗
7. 10.1023/A:101606310937310.1023/A:1016063109373 ↗
8. 10.1016/S0264-410X(96)00183-110.1016/S0264-410X(96)00183-1 ↗
9. 10.1023/B:PHAM.0000041443.17935.3310.1023/B:PHAM.0000041443.17935.33 ↗
10. Eldridge JH · Curr Top Microbial Immun · 1989 · 146 · 59
11. 10.1128/iai.59.9.2978-2986.199110.1128/iai.59.9.2978-2986.1991 ↗
12. 10.3109/0363904980908994210.3109/03639049809089942 ↗
13. 10.1016/0264-410X(95)00011-O10.1016/0264-410X(95)00011-O ↗
14. 10.1016/S0032-3861(98)00142-610.1016/S0032-3861(98)00142-6 ↗
15. 10.1016/S0144-8617(96)00118-X10.1016/S0144-8617(96)00118-X ↗
16. 10.1016/0032-3861(92)90610-910.1016/0032-3861(92)90610-9 ↗
17. 10.1023/A:101192901660110.1023/A:1011929016601 ↗
18. Indian Pharmacopoeia · Government of India · 1985 · 2 · A39
19. 10.1016/j.ijpharm.2004.12.02610.1016/j.ijpharm.2004.12.026 ↗
20. 10.1163/156856294X0056310.1163/156856294X00563 ↗
21. 10.1016/S0378-5173(98)00367-610.1016/S0378-5173(98)00367-6 ↗
22. 10.1023/A:101199861526710.1023/A:1011998615267 ↗
23. 10.1016/0022-1759(86)90314-510.1016/0022-1759(86)90314-5 ↗
24. 10.1128/iai.13.1.204-210.197610.1128/iai.13.1.204-210.1976 ↗
25. 10.1211/jpp.58.6.000410.1211/jpp.58.6.0004 ↗
26. 10.1016/0264-410X(93)90387-D10.1016/0264-410X(93)90387-D ↗
27. O’Hagan DT · Immunology · 1991 · 73 · 239
28. 10.1007/s00268-002-6497-z10.1007/s00268-002-6497-z ↗
29. 10.1111/j.0818-9641.2004.01272.x10.1111/j.0818-9641.2004.01272.x ↗
30. 10.1128/iai.65.5.1716-1721.199710.1128/iai.65.5.1716-1721.1997 ↗
31. 10.1111/j.1365-2222.2005.02287.x10.1111/j.1365-2222.2005.02287.x ↗
32. 10.1016/S0264-410X(03)00347-510.1016/S0264-410X(03)00347-5 ↗
33. 10.1016/S0169-409X(01)00197-110.1016/S0169-409X(01)00197-1 ↗
34. 10.1146/annurev.iy.04.040186.00210110.1146/annurev.iy.04.040186.002101 ↗
35. 10.1021/js960281210.1021/js9602812 ↗